02067naa a2200313 a 450000100080000000500110000800800410001902200140006002400560007410000170013024501450014726000090029230000120030152010870031365300190140065300190141965300170143865300440145570000230149970000220152270000160154470000180156070000160157870000230159470000190161770000250163670000220166177300700168321326322022-06-10       2021    bl uuuu     u00u1 u    #d  a0141-81307 ahttps://doi.org/10.1016/j.ijbiomac.2021.02.0312DOI1 aSILVA, D. S.  aN-(2-hydroxy)-propyl-3-trimethylammonium, O-palmitoyl chitosanbSynthesis, physicochemical and biological properties.h[electronic resource]  c2021  a558?568  aTwo samples of N-(2-hydroxy)-propyl-3-trimethylammonium, O-palmitoyl chitosan (DPCat) with different average degrees of quaternization named as DPCat35 (DQ = 35%) and DPCat80 (DQ = 80%), were successfully synthesized by reacting glycidyltrimethylammonium chloride (GTMAC) with O-palmitoyl chitosan (DPCh) derivative (DS = 12%). Such amphiphilic derivatives of chitosan were fully water-soluble at 1.0 &lt pH &lt 12.0 and showed significant electrostatic stability enhancement of a self-assembly micellar nanostructure (100–320 nm) due to its positively-charged out-layer. In vitro mucoadhesive and cytotoxicity essays toward healthy fibroblast cells (Balb/C 3T3 clone A31 cell), human prostate cancer (DU145) and liver cancer (HepG2/ C3A) cell lines revealed that the biological properties of DPCat derivatives were strongly dependent on DQ. Additionally, DPCat35 had better interactions with the biological tissue and with mucin glycoproteins at pH 7.4 as well as exhibited potential to be used on the development of drug delivery systems for prostate and liver cancer treatment.  aCancer therapy  aCytocompatible  aMucoadhesive  aPositively-charged amphiphilic chitosan1 aFACCHINATTO, W. M.1 aSANTOS, D. M. dos1 aBONI, F. I.1 aVALDES, T. A.1 aLEITÃO, A.1 aGREMIÃO, M. P. D.1 aCOLNAGO, L. A.1 aCAMPANA-FILHO, S. P.1 aRIBEIRO, S. J. L.  tInternational Journal of Biological Macromoleculesgv. 178, 2021.